RESUMEN
BACKGROUND: Given the high incidence of sudden death in patients with chronic heart failure (CHF) and the efficacy of implantable cardioverter-defibrillators, an appropriate tool for the prediction of sudden death is desirable. B-type natriuretic peptide (BNP) has prognostic significance in CHF, and the stimuli for its production cause electrophysiological abnormalities. This study tests BNP levels as a predictor of sudden death. METHODS AND RESULTS: BNP levels, in addition to other neurohormonal, clinical, and hemodynamic variables, were obtained from 452 patients with a left ventricular ejection fraction (LVEF) < or =35%. For prediction of sudden death, only survivors without heart transplantation (HTx) or a mechanical assist device and patients who died suddenly were analyzed. Up to 3 years, 293 patients survived without HTx or a mechanical assist device, 89 patients died, and 65 patients underwent HTx. Mode of death was sudden in 44 patients (49%), whereas 31 patients (35%) had pump failure and 14 patients (16%) died from other causes. Univariate risk factors of sudden death were log BNP (P=0.0006), log N-terminal atrial natriuretic peptide (P=0.003), LVEF (P=0.005), log N-terminal BNP (P=0.006), systolic blood pressure (P=0.01), big endothelin (P=0.03), and NYHA class (P=0.04). In the multivariate model, log BNP level was the only independent predictor of sudden death (P=0.0006). Using a cutoff point of log BNP <2.11 (130 pg/mL), Kaplan-Meier sudden death-free survival rates were significantly higher in patients below (99%) compared with patients above (81%) this cutoff point (P=0.0001). CONCLUSION: BNP levels are a strong, independent predictor of sudden death in patients with CHF.
Asunto(s)
Factor Natriurético Atrial/sangre , Muerte Súbita Cardíaca , Insuficiencia Cardíaca/sangre , Insuficiencia Cardíaca/mortalidad , Antagonistas Adrenérgicos beta/uso terapéutico , Alprostadil/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Arritmias Cardíacas/tratamiento farmacológico , Arritmias Cardíacas/mortalidad , Cardiotónicos/uso terapéutico , Enfermedad Crónica , Comorbilidad , Muerte Súbita Cardíaca/epidemiología , Endotelina-1 , Endotelinas/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Insuficiencia Cardíaca/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Péptido Natriurético Encefálico , Valor Predictivo de las Pruebas , Pronóstico , Precursores de Proteínas/sangre , Factores de Riesgo , Volumen Sistólico , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
BACKGROUND: Endothelin antagonists represent a new approach to neurohumoral treatment in patients with chronic heart failure. In this study, the new selective endothelin-A receptor antagonist, darusentan, was compared with placebo for 3 weeks in patients with severe heart failure on top of standard treatment that included angiotensin-converting enzyme (ACE) inhibitors and beta-blockers. Effects on neurohormones and hemodynamics were evaluated. METHODS: Consecutive patients with severe heart failure (New York Heart Association [NYHA] Grade III) were included in this neurohumoral sub-study of an international, multi-center, double-blind, placebo-controlled study of darusentan, and randomized to darusentan (n = 23) or placebo (n = 8). The mean left ventricular ejection fraction was 19 +/- 6% at the beginning of the study. Patients were randomized to different dosage levels of darusentan (30, 100, or 300 mg) for 3 weeks. Hemodynamics were obtained by right heart Swan-Ganz catheterization at entry and end of study. Serial assessment of plasma brain natriuretic peptide (BNP), big-endothelin, and pro-atrial natriuretic peptide (pro-ANP) was performed. In the active treatment group, 1 patient died due to worsening heart failure, 1 patient received elective heart transplantation, and 2 patients stopped taking the medication due to vertigo. In the placebo group, 1 patient was excluded due to non-compliance. RESULTS: Overall, the mean dose of darusentan was 144 +/- 125 mg/day (30 mg: n = 8; 100 mg: n = 4; 300 mg: n = 7). Significant benefits in hemodynamic variables were found after 3 weeks only in patients receiving darusentan (baseline vs end of study: cardiac index: 2.0 +/- 0.3 vs 2.6 +/- 0.5 liters/min m(2), p < 0.0001; mean pulmonary artery pressure: 35 +/- 9 vs 33 +/- 8 mm Hg, p < 0.05; heart rate: 79 +/- 16 vs 71 +/- 10 beats/min, p < 0.01). A significant reduction in mean arterial blood pressure was observed with the endothelin antagonist (baseline 80 +/- 8 vs end 73 +/- 8 mm Hg, p < 0.01). BNP decreased significantly in patients with darusentan (90 +/- 87 at entry vs 63 +/- 67 fmol/ml after 3 weeks, p < 0.01), whereas big-endothelin remained unchanged. Pro-ANP tended to decrease in the active treatment group, but did not reach statistical significance. CONCLUSION: Significant hemodynamic and neurohumoral benefits were observed in patients with severe heart failure receiving the selective endothelin antagonist darusentan.
Asunto(s)
Antagonistas de los Receptores de la Endotelina A , Insuficiencia Cardíaca/tratamiento farmacológico , Fenilpropionatos/uso terapéutico , Pirimidinas/uso terapéutico , Factor Natriurético Atrial/sangre , Factor Natriurético Atrial/metabolismo , Presión Sanguínea/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Endotelina-1/sangre , Endotelina-1/metabolismo , Femenino , Insuficiencia Cardíaca/metabolismo , Pruebas de Función Cardíaca , Hemodinámica/efectos de los fármacos , Humanos , Pruebas de Función Hepática , Masculino , Persona de Mediana Edad , Péptido Natriurético Encefálico/sangre , Péptido Natriurético Encefálico/metabolismoRESUMEN
BACKGROUND: Endothelin (ET) and natriuretic peptides have prognostic significance in chronic heart failure (CHF). Because stimuli for forming these neurohormones differ, this study investigates whether their prognostic power depends on clinical stage and on length of the observation period. METHODS: Plasma big ET, B-type natriuretic peptide (BNP), N-terminal BNP (N-BNP), and N-terminal atrial natriuretic peptide (N-ANP), in addition to 11 clinical and hemodynamic variables, were obtained from 452 patients with left ventricular ejection fraction (LVEF) =35%. According to their New York Heart Association class and LVEF, patients were stratified into Group A, mild CHF (n = 114); Group B, moderate CHF (n = 210); and Group C, severe CHF (n = 128). To predict the combined end-point of death or urgent heart transplantation, a multivariate analysis was performed after an observation period of up to 1, 2, and 3 years in all patients and in each sub-group. RESULTS: Best independents predictors were as follows: All patients: up to 1 year, big ET (p < 0.0001, chi-square = 59); and 2 and 3 years, log N-ANP (p < 0.0001, chi-square = 68; p < 0.0001, chi-square = 89). Group A: up to 2 and 3 years, log N-ANP (p < 0.001, chi-square = 12; p < 0.0001, chi-square = 25). Group B: up to 1 and 3 years, log N-ANP (p < 0.0001, chi-square = 16; p < 0.0001, chi-square = 22); and 2 years, log N-BNP (p < 0.0001, chi-square = 19). Group C: up to 1, 2, and 3 years, big ET (p < 0.0001, chi-square = 23; p < 0.0001, chi-square = 22; p < 0.0001, chi-square = 20). CONCLUSION: Big ET was the best independent marker for 1-year prognosis in severe CHF, whereas natriuretic peptides (especially N-ANP) were better markers for 2- and 3-year prognoses in mild and moderate CHF.
Asunto(s)
Gasto Cardíaco Bajo/diagnóstico , Endotelina-1/sangre , Biomarcadores , Gasto Cardíaco Bajo/sangre , Gasto Cardíaco Bajo/clasificación , Gasto Cardíaco Bajo/mortalidad , Enfermedad Crónica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Péptidos Natriuréticos/sangre , Pronóstico , Factores de Riesgo , Disfunción Ventricular Izquierda/sangre , Disfunción Ventricular Izquierda/diagnósticoRESUMEN
BACKGROUND: The purpose of this study was to investigate the impact of successful heart transplantation in patients with refractory heart failure receiving bridging therapy on sequential plasma levels of big endothelin, norepinephrine, atrial natriuretic peptide and aldosterone. METHODS: Fourteen patients (2 women, 12 men) accepted for heart transplantation were studied. All had severe chronic heart failure refractory to optimized oral therapy with angiotensin-converting enzyme inhibitors and furosemide, were in New York Heart Association functional Class IV, and had a left ventricular ejection fraction of <15%, Right heart catheterization was performed in all patients (cardiac index 1.9 +/- 0.1 liters/min. m(2), pulmonary capillary wedge pressure 30 +/- 2 mmHg, systemic vascular resistance index 2,827 +/- 253 dyn. s/cm(5). m(2)). As bridging therapy, patients received either prostaglandin E(1), prostaglandin E(1) and dobutamine or dobutamine alone as a continuous infusion. Neurohumoral variables were measured prior to bridging therapy and 3.5 months before and 7 and 10 months after successful heart transplantation. RESULTS: Big endothelin, norepinephrine and atrial natriuretic peptide plasma levels decreased from 7.4 +/- 2.9 fmol/ml, 1112 +/- 686 pg/ml and 366 +/- 312 pg/ml to 6.0 +/- 4.5 fmol/ml, 720 +/- 503 pg/ml and 198 +/- 160 pg/ml, respectively, after bridging therapy, and further to 2.1 +/- 0.9 fmol/ml (p < 0.00001 vs baseline), 527 +/- 31 pg/ml (p < 0.02 vs baseline) and 115 +/- 70 pg/ml (p < 0.03 vs baseline), respectively, after cardiac transplantation. Aldosterone plasma levels decreased from 242 +/- 220 pg/ml to 183 +/- 142 pg/ml during bridging therapy and increased after heart transplantation to 252 +/- 189 pg/ml. Plasma creatinine levels increased from 1.2 +/- 0.4 mg/dl at baseline to 1.4 +/- 0.2 mg/dl after transplantation (NS). CONCLUSIONS: The study suggests that excessive overproduction of big endothelin, atrial natriuretic peptide and norepinephrine is predominantly related to pump failure and, after cardiac transplantation, a moderate spillover of big endothelin persists. Its specific origin, however, remains to be elucidated. Furthermore, our data suggest a protective effect of prostaglandin E(1) on kidney function after heart transplantation.
Asunto(s)
Endotelinas/sangre , Trasplante de Corazón , Cuidados Intraoperatorios , Cuidados Posoperatorios , Anciano , Aldosterona/sangre , Factor Natriurético Atrial/sangre , Austria , Biomarcadores/sangre , Nitrógeno de la Urea Sanguínea , Creatinina/sangre , Femenino , Insuficiencia Cardíaca/sangre , Insuficiencia Cardíaca/fisiopatología , Insuficiencia Cardíaca/cirugía , Humanos , Masculino , Persona de Mediana Edad , Isquemia Miocárdica/sangre , Isquemia Miocárdica/fisiopatología , Isquemia Miocárdica/cirugía , Norepinefrina/sangre , Presión Esfenoidal Pulmonar/fisiología , Resultado del Tratamiento , Resistencia Vascular/fisiologíaRESUMEN
BACKGROUND: Neurohormones and cytokines have been associated with poor prognosis in patients with congestive heart failure. However, direct comparisons between them are rare and the best predictor for worsening of heart failure remains to be elucidated. The aim of the study was to identify independent predictors for worsening of heart failure. METHODS: We studied 100 patients with congestive heart failure (LVEF Asunto(s)
Insuficiencia Cardíaca/sangre
, Interleucina-6/sangre
, Péptido Natriurético Encefálico/sangre
, Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico
, Progresión de la Enfermedad
, Femenino
, Insuficiencia Cardíaca/tratamiento farmacológico
, Humanos
, Masculino
, Persona de Mediana Edad
, Pronóstico
, Modelos de Riesgos Proporcionales
, Análisis de Regresión
RESUMEN
BACKGROUND: In patients with heart failure, B-type natriuretic peptides (BNP, N-BNP) and atrial natriuretic peptide (ANP) are established prognostic markers. However, circulating interleukin (IL)-6-related cytokines and soluble glycoprotein 130 (sgp130), their common subunit for signal transduction, are also increased. We hypothesized that levels of circulating sgp130 and cardiac peptides provide independent prediction of worsening pump failure in the long term. METHODS: A series of 76 patients (77% male, 54 ischemic and 17 nonischemic, left ventricular ejection fraction 22% +/- 7%) had blood samples drawn for assay of sgp130, oncostatin-M, N-ANP, N-BNP, and BNP. A composite end point of worsening pump failure (requiring hospitalization, intravenous therapy, or urgent heart transplantation) and pump failure death was used for follow-up. RESULTS: During follow-up (up to 7 years), rate of worsening pump failure was 22.3%, including death. N-ANP (5666 +/- 3100 vs 7850 +/- 12164 fmol/ml), N-BNP (278 +/- 284 vs 250 +/- 297 pmol/ml), and oncostatin-M (15 +/- 28 vs 16 +/- 63 pg/ml) were similar in those who incurred worsening pump failure and in others. Mean sgp130 levels were 389 +/- 123 ng/ml in patients who developed worsening heart failure (Group A) and 289 +/- 123 ng/ml in stable patients (Group B; p < 0.0001). Mean BNP was 567 +/- 774 pg/ml in Group A and 307 +/- 324 pg/ml in Group B (p < 0.05). By using a cutoff value of 286 ng/ml for gp130 in Kaplan-Meier analysis, we found that the rate of freedom from worsening heart failure was significantly higher in patients below compared with patients above this cutoff point (p = 0.03). In univariate and multivariate Cox regression analysis, only sgp130 emerged as statistically significant (p < 0.001). CONCLUSIONS: In addition to BNP, sgp130 could be useful in identifying patients at high risk for heart failure progression.